Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer Developed technology rights by Quarter
Developed technology rights — Net carrying amount ($M) ($M)
Pfizer Developed technology rights: $28,287M in Q2 2026, down 13.3% from a year earlier.
Latest, Q2 2026
28,287
Period ended Jun 28, 2026
Change on a year earlier
-13.3%
32,629 in Q2 2025
History
37 quarters
Since Q4 2015
Sources
36
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Goodwill & Other Intangible Assets Footnote.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Developed technology rights — Net carrying amount ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 28, 2026 | 28,287 | -13.3% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 29, 2026 | 29,905 | -9.9% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 30,458 | -11.3% | Form 10-Q (filed 2026-08-04) ↗ |
| Q3 2025 | Sep 28, 2025 | 32,163 | -8.9% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 29, 2025 | 32,629 | -10.7% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2025 | Mar 30, 2025 | 33,180 | -12.2% | Form 10-Q (filed 2025-05-05) ↗ |
| Q4 2024 | Dec 31, 2024 | 34,353 | -11.4% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2024 | Sep 29, 2024 | 35,306 | +31.5% | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 36,543 | +30.5% | Form 10-Q (filed 2024-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 37,783 | +34.5% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 38,773 | +32.3% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2023 | Oct 1, 2023 | 26,855 | +53.4% | Form 10-Q (filed 2023-11-08) ↗ |
| Q2 2023 | Jul 2, 2023 | 27,994 | +53.9% | Form 10-Q (filed 2023-08-09) ↗ |
| Q1 2023 | Apr 2, 2023 | 28,086 | +49.3% | Form 10-Q (filed 2023-05-10) ↗ |
| Q4 2022 | Dec 31, 2022 | 29,297 | +49.4% | Form 10-K (filed 2024-02-22) ↗ |
| Q3 2022 | Oct 2, 2022 | 17,509 | -15.3% | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2022 | Jul 3, 2022 | 18,193 | -15.8% | Form 10-Q (filed 2022-08-10) ↗ |
| Q1 2022 | Apr 3, 2022 | 18,815 | -15.3% | Form 10-Q (filed 2022-05-11) ↗ |
| Q4 2021 | Dec 31, 2021 | 19,614 | -12.9% | Form 10-K (filed 2023-02-23) ↗ |
| Q3 2021 | Oct 3, 2021 | 20,673 | -13.3% | Form 10-Q (filed 2021-11-12) ↗ |
| Q2 2021 | Jul 4, 2021 | 21,616 | -14.4% | Form 10-Q (filed 2021-08-12) ↗ |
| Q1 2021 | Apr 4, 2021 | 22,217 | -10.2% | Form 10-Q (filed 2021-05-13) ↗ |
| Q4 2020 | Dec 31, 2020 | 22,508 | -11.2% | Form 10-K (filed 2022-02-24) ↗ |
| Q3 2020 | Sep 27, 2020 | 23,840 | -18.3% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2020 | Jun 28, 2020 | 25,244 | -11.7% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2020 | Mar 29, 2020 | 24,736 | -16.0% | Form 10-Q (filed 2020-05-07) ↗ |
| Q4 2019 | Dec 31, 2019 | 25,357 | -17.0% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2019 | Sep 29, 2019 | 29,180 | -15.0% | Form 10-Q (filed 2019-11-07) ↗ |
| Q2 2019 | Jun 30, 2019 | 28,590 | -12.7% | Form 10-Q (filed 2019-08-08) ↗ |
| Q1 2019 | Mar 31, 2019 | 29,465 | -12.6% | Form 10-Q (filed 2019-05-09) ↗ |
| Q4 2018 | Dec 31, 2018 | 30,535 | -12.2% | Form 10-K (filed 2020-02-27) ↗ |
| Q3 2018 | Sep 30, 2018 | 34,337 | – | Form 10-Q (filed 2018-11-08) ↗ |
| Q2 2018 | Jul 1, 2018 | 32,753 | – | Form 10-Q (filed 2018-08-09) ↗ |
| Q1 2018 | Apr 1, 2018 | 33,726 | – | Form 10-Q (filed 2018-05-10) ↗ |
| Q4 2017 | Dec 31, 2017 | 34,765 | +3.0% | Form 10-K (filed 2019-02-28) ↗ |
| Q4 2016 | Dec 31, 2016 | 33,740 | +10.9% | Form 10-K (filed 2018-02-22) ↗ |
| Q4 2015 | Dec 31, 2015 | 30,419 | – | Form 10-K (filed 2017-02-23) ↗ |
Cite this data
StockData. (2026). Pfizer Developed technology rights ($M), quarterly Q4 2015–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/intang-net-dev
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.